Oncology

Latest News

Offline data augmentation can significantly enhance deep learning techniques, improving classification performance compared to models trained solely on original clinician skin images. | Image Credit: Alexander - stock.adobe.com

Optimized Deep Learning Model Classifies Smartphone Images of Malignant Skin Lesions

By AJMC Contributor

May 12th 2025

Across various classes, the researchers identified a model that, when coupled with appropriate data augmentation and optimization partner, may help aid in the detection of skin cancer.

With inconclusive treatment guidance and varying findings from clinical trials, the prognosis of transformed SCLC remains poor. | Image credit: Crystal Light - stock.adobe.com

Whole Exome Sequencing Identifies Distinct Profile of Transformed SCLC

By AJMC Contributor

May 12th 2025

The report suggests a TBS cutoff value of 3 will serve as a meaningful prognostic tool in HCC, but differences in patient populations and imaging techniques may affect the value of that cutoff, the authors noted. | Image credit: Jo Panuwat D - stock.adobe.com

HCC Tumor Burden Score Predicts Long-Term Outcomes Following MWA

By Jared Kaltwasser

May 7th 2025

Doctor showing lung x ray | Image credit: didesign – stock.adobe.com

Tarlatamab Safety Varies Between Clinical and Real-World SCLC Trials

By Hayden E. Klein

May 6th 2025

CureCancer | Image Credit: © MMPhoto21-sotck.adobe.com

COA 2025: Insight, Innovation, and Independent Strength

By Maggie L. Shaw

May 5th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

March 3rd 2015

Study Evaluates Cost-Benefit of US Spending on Cancer Care

The study in Health Affairs published by Samir Soneji, PhD, an assistant professor at Dartmouth's Geisel School of Medicine and The Dartmouth Institute for Health Policy & Clinical Practice, found that despite a sharp rise in healthcare spending,caner mortality rates are very high in the US compared to Western Europe.

March 3rd 2015

Study Findings Validate the Use of Adjuvant Systemic Therapy in Gastrointestinal Tumors

The use of adjuvant systemic therapy for localized gastrointestinal stromal tumors has significantly increased over time, a new study published in the American Journal of Clinical Oncology, has found, and patients treated with the therapy have better survival than those treated with surgery alone, researchers say.

March 3rd 2015

Novation Survey Underscores Problems With Genetech's Specialty Drug Distribution Changes

The study found that following Genetech's decision to restrict the distribution of it's 3 popular cancer medications through specific specialty distributors, patient access to the drugs has reduced while costs have increased.

March 2nd 2015

Kyprolis Trumps Velcade in Multiple Myeloma Trial

Results released by Amgen, who bought the molecule from Onyx, show that Kyprolis yielded better results when used as second-line in relapsed patients.

March 2nd 2015

Web-Based Tool Designed to Improve Quality of Care in Thyroid Cancer

The Thyroid Cancer Clinical Registry is expected to improve quality of patient care as patient data would be readily available to all physicians involved in the patients care; however former Commission on Cancer chair Frederick L Greene, MD, wonders whether physicians would take the time to enter the clinical data into the system as required.

February 28th 2015

Urine Test for Bladder Cancer Could Aid Early Detection

A simple urine test could help to guide clinicians in the treatment of bladder cancer patients, researchers believe. Being able to reliably identify those patients with the most aggressive cancers early via urine tests, and expediting aggressive therapeutic strategies, may significantly improve outcomes, they say.

February 27th 2015

Opdivo Gets Priority Review for NSCLC

BMS announced in a press release today that Opdivo (nivolumab), approved for advanced melanoma, has received priority review from the FDA for treating patients with advanced NSCLC.

February 27th 2015

Studies Highlight Limitations in Emergency Provider Understanding of End-of-Life Care Choices

Emergency care providers vary in their understanding of a type of medical order intended to communicate seriously ill patients' choices for life-sustaining treatments, according to a pair of studies recently published.

February 27th 2015

AJMC Panel Sees Advantages in FDA Regulation of Molecular Diagnostic Tests for Cancer Care

The American Journal of Managed Care convened a discussion of 2 leading clinicians and 2 medical directors for leading payers, all of whom saw some merit in FDA's plans to bring oversight to the diagnostic testing market. The strongest advocate for greater FDA oversight was Daniel F. Hayes, MD, clinical director of the Breast Oncology Program at the University of Michigan, who will be a future president of the American Society of Clinical Oncology.

February 27th 2015

Community Oncology Alliance Announces Launch of Accreditation Pilot for OMH

Ten oncology practices around the nation will initiate their accreditation process this year, which includes an on-site survey bu the Commission on Cancer.

February 26th 2015

NICE Guidelines for Bladder Cancer Can Minimize Care Variance

NICE's first guideline on bladder cancer aims to improve the diagnosis and management of the seventh most common cancer in the UK.

Dr Ira Klein Discusses the CMS Oncology Care Model

February 26th 2015

Dr Ira Klein Discusses the CMS Oncology Care Model

The goals of the new CMS Oncology Care Model align very nicely with what payers want, according to Ira M. Klein, MD, MBA, FACP, national medical director, clinical thought leadership, office of the chief medical officer, Aetna.

February 26th 2015

Basket Trials Have FDA Support, But Will They Deliver?

Following the introduction of adaptive clinical trials, cancer researchers are now working on another revolutionary model, and they have the FDA's support in this effort. Named basket studies because they group different cancers together based on the driver mutation rather than the tumor of origin, these trials do not use the standard treatment as a control group, but look for a "Yes" or "No" response.

February 25th 2015

Fred Hutch Receives Multimillion Dollar Cancer Research Grant from PCORI

Project to research better way to treat neutropenia is 1 of 5 to get latest funding from Patient-Centered Outcomes Research Institute.

February 25th 2015

NICE Rejects Provenge, Says Treatment is Not Cost-Effective

The governing body for public health in the UK, National Institute for Health and Care Excellence, has refused to fund Provenge citing a high-price for the benefit the tretament provides. This may not be the best news for Valeant Pharmaceuticals which recently bought the regimen from the bankrupt Dendreon Corp.

February 24th 2015

Shared Decision-Making in Cancer Has Several Variables

A study published in the journal Cancer provides insights that may help physicians understand patients' preferences regarding their care, which may be crucial for optimizing patient participation in treatment decisions.

February 24th 2015

Study Results Could Improve Quality of Life in Pediatric ALL

The study, conducted in 2 separate patient cohorts at St. Jude Children's Hospital and the Children's Oncology Group and published in the The Journal of the American Medical Association, found that children with gene variants in the CEP72 gene were more sensitive to vincristine-induced peripheral neuropathy.

February 24th 2015

Study Warns Against Use of VEGF Inhibitors in Advanced Kidney Cancer

Interim analysis of a clinical trial evaluating adjuvant sorafenib, sunitinib or placebo in patients with advanced renal cell carcinoma found the recurrence rates and the disease-free survival were similar between all three treatment regimens.

February 23rd 2015

First HDAC Inhibitor, Developed by Novartis, Approved for Multiple Myeloma

Study results showed participants receiving Farydak with bortezomib and dexamethasone saw a progression-free survival for about 10.6 months,compared to 5.8 months in participants treated with bortezomib and dexamethasone alone.

February 23rd 2015

Coalition of Leading Cancer Centers Aims to Improve Personalized Treatment

"The growth of ORIEN coincides with President Obama's announcement and the recognition that molecularly targeted medicine holds tremendous promise for all disease, particularly cancer," said Michael Caligiuri, MD, director of The Ohio State University Comprehensive Cancer Center and CEO of the James Cancer Hospital and Solove Research Institute.

February 23rd 2015

BMS Deals Set to Boost Company's Oncology Pipeline

The deals, with Flexus and Rigel, will add another molecule to the company's immunotherapy pipeline and also provide access to a TGF-beta receptor inhibitor to be used in combination with Yervoy and Opdivo.

February 23rd 2015

Taiho's NDA for mCRC Under FDA Review

The TAS-102 RECOURSE trial met the primary efficacy endpoint of statistically significant improvement in overall survival versus placebo, and the results of the trial form the basis of the NDA.

February 23rd 2015

Expert Analysis on Managing mCRC

At the 26th International Congress on Anti-Cancer Treatment in Paris, France, earlier this month, oncologists deliberated on the current understanding of metastatic colorectal cancer and the available treatment options. Recent work has shown that there are 4 or 5 different subtypes of the disease, which may call for personalized therapeutic strategies.

February 21st 2015

Managed Care Minute: February 21, 2015

A one-minute look at managed care news during the week of February 16, 2015, including extended open enrollment under the Affordable Care Act and shared decision-making for cancer treatments.

February 20th 2015

Celgene's Revlimid Receives Expanded Approval in Europe Following Similar FDA Approval

After the FDA approved lenalidomide for use in chemotherapy-naive multiple myeloma (MM) patients, the European Commission has followed suit. Revlimid was approved today by EC in MM patients, previously untreated and transplant-ineligible.

February 20th 2015

Study Underscores the Potential of Mobile Health App in Healthcare Decisions

The study, conducted at the Columbia University School of Nursing, found that mobile apps with decision support features resulted in significantly higher diagnosis rates than apps with only bare-bones tools for recording results from a patient exam.

February 20th 2015

UCLA Study Points to Need for Informed Decision-Making in Prostate Cancer

The study evaluated SEER data of over 37,000 prostate cancer patients and found an overwhelming majority of patients (58%) received radiation treatment regardless of overall disease prognosis. The lead study author hopes these findings enlighten the public and allow physicians to make an informed decision when it comes to the best treatment option for men who may or may not benefit from radiation therapy in the long run.

February 20th 2015

FDA Authorizes Sale of First Direct-to-Consumer Genetic Test

Developed by the company 23andMe, the test identifies carriers of a gene mutation that could determine the susceptibility of a person's offspring to Bloom Syndrome.

February 19th 2015

Study Results Challenge CMS Position on Follow-Up Scans in Cancer Patients

Published in the Journal of Nuclear Medicine, the authors show that a fourth and subsequent follow-up PET/CT scan in lung cancer patients was associated with treatment change.

February 19th 2015

Biomarker That Could Predict Survival After CRC Surgery Discovered

Research scientists at the Macquarie University and Concord Repatriation General Hospital in Australia have discovered that expression of the cell surface protein uPAR can predict survival after colorectal cancer (CRC) surgery. The study found that patients expressing uPAR may have undetectable cancer metastasis and dramatically poorer survival.

...

136 137 138 139 140 141 142 143 144

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions